GHRP-2 vs Tesamorelin
Well Studied vs FDA Approved
synergistic Mechanism-based · 55% GHRP-2 and Tesamorelin amplify GH release through complementary mechanisms (GHRH primes, GHRP triggers). This is a well-established synergistic combination — expect significantly greater GH output than either alone.
Molecular Data
GHRP-2 Tesamorelin
Weight 817.9 Da 5,135.9 Da
Half-life ~30 minutes 26-38 minutes
Chain 6 amino acids 44 amino acids
Type Synthetic hexapeptide GHRH analog
Key Benefits
GHRP-2
01 Potent stimulation of natural growth hormone release
02 Enhanced muscle growth and recovery
03 Improved body composition and fat metabolism
04 Better sleep quality and recovery
05 Increased appetite (can be beneficial for bulking)
06 Maintains natural GH pulsatile release patterns
07 Synergistic effects when combined with GHRH peptides
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
GHRP-2
100-300 mcg / 2-3x daily
GH optimization 100-150 mcg 2-3x daily
Enhanced results 200-300 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Pre-sleep protocol 100-200 mcg Before bed
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
GHRP-2
Increased appetite (less than GHRP-6)
Mild water retention
Tingling or numbness in extremities
Tiredness or lethargy after injection
Mild headache
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
Diabetic retinopathy
WADA prohibited for competitive athletes
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
GHRP-2 Tesamorelin
Status Well Studied FDA Approved
References 3 studies 5 studies
Latest — June 2025
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.